ASMB · Assembly Biosciences, Inc. · Investor Relations
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Upcoming events
| Date | Event | Type |
|---|---|---|
| 2026-11-05 00:00 UTC | American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2026 | Event |
Recent news
| Date | Headline |
|---|---|
| 2026-10-05 |
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today |
| 2026-09-10 |
Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. |
| 2026-09-08 |
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes – – Cash runway remains projected into 2029, including the first $75 million collaboration extension fee from Gilead payable in Q4 2026 – SOUTH SAN FRANCISCO, |
| 2026-08-13 |
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – – Completed $115 million gross financing to support advancement of pipeline programs through key development milestones – – GS-1179 |
| 2026-05-28 |
Assembly Biosciences Announces Upcoming Investor Conference Presentations
SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will participate in fireside chats at two upcoming |
| 2026-05-26 |
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the closing of its previously announced underwritten registered offering of |
| 2026-05-22 |
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the pricing of an underwritten, registered offering (the offering) of an |
| 2026-05-22 |
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 – – Builds on completed Phase 1a study and ongoing development in HDV – SOUTH SAN FRANCISCO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. |
| 2026-05-13 |
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced topline clinical data on ABI-6250, an investigational oral hepatitis D virus (HDV) |
| 2026-05-11 |
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, chief medical officer, will present during the Bank of |
| 2026-05-07 |
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
– Completed Phase 1b studies for ABI-5366 and ABI-1179, helicase-primase inhibitors for recurrent genital herpes – – Completed chronic toxicology studies for ABI-6250, an oral small-molecule entry inhibitor candidate for chronic hepatitis delta virus; Phase 2 initiation anticipated Q4 2026 – SOUTH |
| 2026-04-09 |
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation – – Phase 1b data from ABI-1179 accepted for late-breaker poster presentation – SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. |
| 2026-03-19 |
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
– Successfully licensed helicase-primase inhibitor program for recurrent genital herpes to Gilead, including candidates ABI-5366 and ABI-1179, following positive Phase 1b interim data; development plan anticipated by mid-2026 – – Phase 2 initiation for ABI-6250, an oral small-molecule entry |
| 2025-12-22 |
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
– Weekly Oral Helicase-Primase Inhibitor Programs' Early Data Potentially Supportive of First New Treatment for Recurrent Genital Herpes in 25 Years – FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 22, 2025-- Gilead Sciences, Inc. |